What is it about?
Gene therapies have unique characteristics compared to typical drug products and the US healthcare system will need to adapt in new ways in order to accommodate them. This White Paper represents ideas generated at a Policy Summit sponsored by the Institute for Clinical and Economic Review (ICER). Attendees included executives from major payer and life science companies. Discussion topics included the curative nature of gene therapies, the challenges in evidence generation and technology assessment, as well as problem of affordability including various pay-over-time options.
Featured Image
Why is it important?
Gene therapies can be paradigm shifting technology for serious conditions where few alternatives exist. However, significant challenges exist and this paper tries to identify some of the tough issues and offer potential ways forward.
Perspectives
I think that gene therapies have the potential to change the way we approach disease in a fundamental way. But a one-time treatment for a life-time benefit poses significant business challenges in the US healthcare system. If we, as a system, cannot figure these challenges out, patients will not benefit, innovation incentives will be damaged, and the potential will not be realized.
William Dreitlein
Institute for Clinical and Economic Review
Read the Original
This page is a summary of: Gene therapy: evidence, value and affordability in the US health care system, Journal of Comparative Effectiveness Research, January 2018, Future Medicine,
DOI: 10.2217/cer-2017-0068.
You can read the full text:
Contributors
The following have contributed to this page
